Back to User profile » Dr Oscar Olvera-Montaño
Papers published by Dr Oscar Olvera-Montaño:
Assessment of the Effectiveness, Tolerability, and Safety of the Preservative-Free Fixed Combination of Timolol, Dorzolamide, and Brimonidine Compared to Separate Therapies in Patients with Glaucoma, a Randomized Controlled Trial
Belalcazar S, Tornero-Jimenez A, Mejia-Morales C, Olvera-Montaño O, Muñoz-Villegas P
Clinical Ophthalmology 2026, 20:580973
Published Date: 19 February 2026
Maximum Tolerated Medical Therapy for Glaucoma: Fixed-Dose Combinations of Timolol, Dorzolamide, Brimonidine with Latanoprost Versus Timolol, Dorzolamide with Latanoprost
Olvera-Montaño O, Mejia-Morales C, Jauregui-Franco RO, Gomez-Mendez SC, Muñoz-Villegas P
Clinical Ophthalmology 2025, 19:2913-2925
Published Date: 22 August 2025
Influence of Environmental Factors with Clinical Signs and Symptoms in the Management of Dry Eye Disease
Muñoz-Villegas P, García-Sánchez G, Jauregui-Franco RO, Quirarte-Justo S, Sánchez-Ríos A, Olvera-Montaño O
Clinical Ophthalmology 2024, 18:2439-2451
Published Date: 30 August 2024
The Effect of Sodium Hyaluronate Eye Drops 2, 4 or 6 Times a Day on Signs and Symptoms of Dry Eye Disease
Muñoz-Villegas PDC, Sánchez-Ríos A, Olvera-Montaño O
Clinical Ophthalmology 2023, 17:2945-2955
Published Date: 6 October 2023
Evaluation of the Rheological Properties, Preclinical Safety, and Clinical Effectiveness of a New Dispersive Ophthalmic Viscoelastic Device for Cataract Surgery
Palacio-Pastrana C, Muñoz-Villegas P, Dániel-Dorantes F, Sánchez-Ríos A, Olvera-Montaño O, Martínez-Montoya YI, Quintana-Hau JD, Baiza-Durán LM
Medical Devices: Evidence and Research 2022, 15:293-305
Published Date: 24 August 2022
Reexamining Ophthalmic Drugs, Safety and Tolerability in Phase 1 Clinical Trials
Muñoz-Villegas P, Navarro-Sánchez AA, Sánchez-Ríos A, Olvera-Montaño O, Baiza-Durán LM
Therapeutics and Clinical Risk Management 2021, 17:1123-1134
Published Date: 21 October 2021
Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab
Muñoz-Villegas P, Sanchez-Rios A, Quinonez-Alvarado MG, Olvera-Montaño O, Quintana-Hau JD, Baiza-Duran L
Journal of Experimental Pharmacology 2021, 13:545-554
Published Date: 31 May 2021
Difluprednate 0.05% versus Prednisolone Acetate Post-Phacoemulsification for Inflammation and Pain: An Efficacy and Safety Clinical Trial
Palacio-Pastrana C, Chávez-Mondragón E, Soto-Gómez A, Suárez-Velasco R, Montes-Salcedo M, Fernández de Ortega L, Nasser-Nasser L, Baiza-Durán L, Olvera-Montaño O, Muñoz-Villegas P
Clinical Ophthalmology 2020, 14:1581-1589
Published Date: 12 June 2020
Comparing The Efficacy Of An Anti-Human VEGF-A Neutralizing Antibody Versus Bevacizumab On A Laser-Induced Choroidal Neovascularization (CNV) Rhesus Monkey Model
Olvera-Montaño O, Baiza-Duran L, Quintana-Hau JD, Quiñonez-Alvarado MG, Zeng W, Gong L, Muñoz-Villegas P
Drug Design, Development and Therapy 2019, 13:3813-3821
Published Date: 4 November 2019
Efficacy and safety of bromfenac 0.09% and sodium hyaluronate 0.4% combination therapy, versus placebo in patients with pterygium I–III for clinical signs on ocular inflammation
Chávez-Mondragón E, Palacio C, Soto-Gómez A, Villanueva-Nájera M, De Wit-Carter G, Suárez-Velasco R, Baiza-Duran L, Olvera-Montaño O, Muñoz-Villegas P
Clinical Ophthalmology 2019, 13:781-787
Published Date: 2 May 2019